Bruzzi P - Search Results

1

Molecular epidemiology: new rules for new tools?

Merlo DF, Sormani MP, Bruzzi P. Merlo DF, et al. Among authors: bruzzi p. Mutat Res. 2006 Aug 30;600(1-2):3-11. doi: 10.1016/j.mrfmmm.2006.05.033. Epub 2006 Jul 14. Mutat Res. 2006. PMID: 16843503

2

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients.

Sormani MP, Bruzzi P, Comi G, Filippi M. Sormani MP, et al. Among authors: bruzzi p. Neurology. 2002 Feb 12;58(3):417-21. doi: 10.1212/wnl.58.3.417. Neurology. 2002. PMID: 11839841 Clinical Trial.

3

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.

Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, Bruzzi P. Gennari A, et al. Among authors: bruzzi p. J Natl Cancer Inst. 2008 Jan 2;100(1):14-20. doi: 10.1093/jnci/djm252. Epub 2007 Dec 25. J Natl Cancer Inst. 2008. PMID: 18159072

4

An unconventional cancer treatment lacking clinical efficacy remains available to Italian cancer patients.

Merlo DF, Beccaro M, Costantini M; Italian Survey of the Dying of Cancer Study Group. Merlo DF, et al. Tumori. 2008 Nov-Dec;94(6):830-2. doi: 10.1177/030089160809400609. Tumori. 2008. PMID: 19267100 Clinical Trial.

5

Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.

Bruzzi P, Del Mastro L, Sormani MP, Bastholt L, Danova M, Focan C, Fountzilas G, Paul J, Rosso R, Venturini M. Bruzzi P, et al. J Clin Oncol. 2005 Aug 1;23(22):5117-25. doi: 10.1200/JCO.2005.02.106. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955906

6

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Sormani MP, et al. Among authors: bruzzi p. Ann Neurol. 2009 Mar;65(3):268-75. doi: 10.1002/ana.21606. Ann Neurol. 2009. PMID: 19334061

7

MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.

Sormani MP, Bruzzi P. Sormani MP, et al. Among authors: bruzzi p. Lancet Neurol. 2013 Jul;12(7):669-76. doi: 10.1016/S1474-4422(13)70103-0. Epub 2013 Jun 3. Lancet Neurol. 2013. PMID: 23743084 Review.

8

Can we measure long-term treatment effects in multiple sclerosis?

Sormani MP, Bruzzi P. Sormani MP, et al. Among authors: bruzzi p. Nat Rev Neurol. 2015 Mar;11(3):176-82. doi: 10.1038/nrneurol.2014.237. Epub 2014 Dec 23. Nat Rev Neurol. 2015. PMID: 25534913 Review.

9

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN beta-1b.

Sormani MP, Bruzzi P, Beckmann K, Wagner K, Miller DH, Kappos L, Filippi M; European Study Group on Interferon Beta-1b in Secondary Progressive MS. Sormani MP, et al. Among authors: bruzzi p. Neurology. 2003 May 13;60(9):1462-6. doi: 10.1212/01.wnl.0000063312.15758.b3. Neurology. 2003. PMID: 12743232 Clinical Trial.

10

Breast cancer incidence trends in European women aged 20-39 years at diagnosis.

Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Gamulin M, Primic-Žakelj M, Bruzzi P, Bouchardy C, Fucic A; AIRTUM WG. Merlo DF, et al. Among authors: bruzzi p. Breast Cancer Res Treat. 2012 Jul;134(1):363-70. doi: 10.1007/s10549-012-2031-7. Epub 2012 Mar 29. Breast Cancer Res Treat. 2012. PMID: 22456983

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

394 results

Search Page